Request an Appointment



Contact us with Questions

Expand Content

Patrick C. Ma, MD, MS


Patrick C. Ma, MD, MS
Department: Translational Hematology and Oncology Research
Director, Aerodigestive Oncology Translational Research THOR
Location: Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
Patrick C. Ma, MD, MS
Department: Hematology and Oncology
Location: Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
Adults Only

Biographical Sketch

Dr. Patrick C. Ma joined the Cleveland Clinic Taussig Cancer Institute in August 2010 as Staff Clinician-Scientist in the Department of Translational Hematology and Oncology Research and Solid Tumor Oncology. He was appointed as Director of Aerodigestive Oncology Translational Research Program at Taussig Cancer Institute. Prior to joining Taussig Cancer Institute, Dr. Ma held the position of Assistant Professor of Medicine at the Case Western Reserve University (CWRU)/University Hospitals Case Medical Center (from 2005) and Attending Physician and Instructor of Medicine at the University of Chicago Pritzker School of Medicine (2003-2005).

Dr. Ma graduated his medical education (M.D.) at the University of Toronto, Canada, where he also completed postgraduate studies in Biochemistry and Family Medicine board certification, before relocating in 1996 to Boston, U.S. Subsequently, Dr. Ma further completed his Internal Medicine residency and then subspecialty postgraduate fellowship training in Hematology-Oncology at Tufts Medical Center, and also Thoracic Oncology Research Fellowship at Dana-Farber Cancer Institute in Boston.

Dr. Ma has a special interest in thoracic malignancies including lung cancer, mesothelioma, and neuroendocrine tumors and cancer genomics. He leads laboratory-based translational and clinical research in aerodigestive oncology, with an emphasis on cancer genomics and personalized targeted therapy. Through his research endeavors, he has been awarded a number of competitive awards and research grants.

Dr. Ma is principal investigator or co-investigator in several lung cancer clinical trials investigating novel targeted therapeutics in lung cancer. He was recently awarded the Department of Defense (DOD) Lung Cancer Promising Clinician Research Award, and 2013 Lerner Research Institute Chair's Innovative Research Fund Award. He acts as peer reviewer for a number of journals including Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, Journal of Thoracic Oncology, Clinical Lung Cancer, Nature Genetics, PNAS and Journal of Clinical Oncology. Dr. Ma has also authored and co-authored numerous peer-reviewed articles and abstracts, reviews and book chapters, and has previously presented at national and international scientific conferences in thoracic oncology.

Education & Fellowships

Fellowship - New England Medical Center
Boston, MA USA
Research Fellowship - Dana-Farber Cancer Institute Harvard Medical School
Thoracic Oncology
Boston, MA USA
Residency - Saint Elizabeth Medical Center
Internal Medicine
Boston, MA USA
Residency - Toronto General Hospital
Family Medicine
Toronto, Ontario, Canada
Medical School - University of Toronto Faculty of Medicine
Toronto Canada
Graduate - University of Toronto
Toronto, Ontario, Canada
Undergraduate - University of Hong Kong
Hong Kong


  • Internal Medicine- Medical Oncology

Specialty Interests

Thoracic oncology, lung cancer, aerodigestive oncology translational research, targeted therapy and novel therapeutics, cancer mutations and molecular profiling, cancer genomics, proteomics and metabolomics, personalized cancer therapy, cancer, esophageal cancer

Awards & Honors

  • ECOG Young Investigator Award (2002)
  • American Society of Clinical Oncology (ASCO) Young Investigator Award (2002)
  • American Association for Cancer Research (AACR)-AstraZeneca-Cancer Research and Prevention Foundation Fellowship in Translational Lung Cancer Research (2003-06)
  • American Cancer Society (ACS) Institutional Research Grant Award, University of Chicago Cancer Research Center, University of Chicago (2003)
  • ACS, Illinois Division and the LUNGevity Foundation Lung Cancer Treatment Research Award (2004)
  • NIH/NCI-K08 Mentored Clinical Scientist Career Development Award (2005-10)
  • ACS Institutional Research Grant Award - Case Comprehensive Cancer Center, Case Western Reserve University (2006)
  • Clinical Research Award (Best Clinical Science Presentation): ECOG-Aventis Young Investigators Symposium 2006
  • Clinical and Translational Science Collaborative (CTSC) Core Facilities Utilization Pilot Grant Award, Case Western Reserve University (2009)
  • Department of Defense, CDMRP-Lung Cancer Research Program, Lung Cancer Promising Clinician Research Grant Award (2010-13)
  • Ohio Cancer Research Associates "Seed Money Cancer Research Award" - Recognized for Outstanding Lung Cancer Research as Past Seed Grant Recipient (2011)
  • 2012 Innovator Award, Cleveland Clinic
  • Best Doctor (Hematology & Oncology), Cleveland Magazine 2013
  • Lerner Research Institute Chair's Innovative Research Fund Award, Cleveland Clinic (2013)


  • American Society of Clinical Oncology (ASCO)
  • American Association for Cancer Research (AACR)
  • International Association for the Study of Lung Cancer (IASLC)
  • Cleveland Center for Stem Cell and Regenerative Medicine
  • Case Comprehensive Cancer Center

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 2/4/2014, Dr. Ma has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Ma receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Daiichi Sankyo, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • Chinese
  • English